ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
ALX Oncology (ALXO) announced a virtual event scheduled for January 23, 2025, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from their ASPEN-06 Phase 2 clinical trial. The trial evaluates evorpacept, their CD47-blocker, in patients with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction cancer.
The data will be presented earlier the same day at the 2025 ASCO GI Symposium in a Rapid Oral Abstract Session. Dr. Kohei Shitara, Director of Gastrointestinal Oncology at National Cancer Center Hospital East in Japan, will present the final analysis of the randomized phase 2 part of the study. The presentation is scheduled for 9:15 a.m. – 10:00 a.m. PT.
ALX Oncology (ALXO) ha annunciato un evento virtuale programmato per il 23 gennaio 2025, alle 13:00 PT/16:00 ET, per discutere i dati aggiornati del loro trial clinico di fase 2 ASPEN-06. Lo studio valuta evorpacept, il loro bloccante CD47, in pazienti affetti da cancro gastrico avanzato HER2-positivo o cancro della giunzione gastroesofagea precedentemente trattati.
I dati verranno presentati nello stesso giorno durante il 2025 ASCO GI Symposium in una Sessione di Abstract Orali Rapidi. Il Dr. Kohei Shitara, Direttore di Oncologia Gastrointestinale presso il National Cancer Center Hospital East in Giappone, presenterà l'analisi finale della parte randomizzata di fase 2 dello studio. La presentazione è programmata dalle 9:15 alle 10:00 PT.
ALX Oncology (ALXO) anunció un evento virtual programado para el 23 de enero de 2025, a la 1:00 p.m. PT/4:00 p.m. ET, para discutir datos actualizados de su ensayo clínico de fase 2 ASPEN-06. El ensayo evalúa evorpacept, su bloqueador de CD47, en pacientes con cáncer gástrico avanzado HER2-positivo o cáncer de la unión gastroesofágica previamente tratados.
Los datos se presentarán el mismo día en el Simposio ASCO GI 2025 en una Sesión de Resúmenes Orales Rápidos. El Dr. Kohei Shitara, Director de Oncología Gastrointestinal en el Hospital Nacional de Cáncer del Este en Japón, presentará el análisis final de la parte aleatorizada de fase 2 del estudio. La presentación está programada de 9:15 a.m. a 10:00 a.m. PT.
ALX Oncology (ALXO)는 2025년 1월 23일 오후 1시 PT/오후 4시 ET에 ASPEN-06 2상 임상 시험의 업데이트된 데이터를 논의하기 위해 예정된 가상 이벤트를 발표했습니다. 이 시험은 HER2 양성의 고급 위암 또는 위식도 연결부암으로 이전 치료를 받은 환자에서 그들의 CD47 차단제 에보르파셉트를 평가합니다.
데이터는 같은 날 2025 ASCO GI 심포지엄의 신속 구두 초록 세션에서 발표됩니다. 일본의 국립암센터 동부 병원 위장관 종양학 회장인 고헤이 시타라 박사가 연구의 무작위 2상 부분에 대한 최종 분석을 발표할 예정입니다. 발표는 오전 9:15부터 10:00까지 PT로 예정되어 있습니다.
ALX Oncology (ALXO) a annoncé un événement virtuel prévu pour le 23 janvier 2025, à 13h00 PT/16h00 ET, pour discuter des données mises à jour de leur essai clinique de phase 2 ASPEN-06. L'essai évalue l'evorpacept, leur bloqueur de CD47, chez des patients ayant déjà été traités pour un cancer gastrique avancé HER2-positif ou un cancer de la jonction gastro-œsophagienne.
Les données seront présentées plus tôt dans la journée lors du Symposium ASCO GI 2025 dans une session de résumés oraux rapides. Le Dr Kohei Shitara, directeur de l'oncologie gastro-intestinale à l'hôpital national du cancer de l'est du Japon, présentera l'analyse finale de la partie randomisée de phase 2 de l'étude. La présentation est prévue de 9h15 à 10h00 PT.
ALX Oncology (ALXO) hat ein virtuelles Event angekündigt, das für den 23. Januar 2025, um 13:00 PT/16:00 ET, geplant ist, um aktualisierte Daten aus ihrer ASPEN-06 Phase-2-Studie zu besprechen. Die Studie bewertet Evorpacept, ihren CD47-Blocker, bei Patienten mit zuvor behandelten HER2-positiven fortgeschrittenen Magenkrebs oder Adenokarzinom des gastroösophagealen Übergangs.
Die Daten werden am selben Tag während des 2025 ASCO GI Symposiums in einer Rapid Oral Abstract Session präsentiert. Dr. Kohei Shitara, Direktor für Gastrointestinale Onkologie im National Cancer Center Hospital East in Japan, wird die endgültige Analyse des randomisierten Phase-2-Teils der Studie präsentieren. Die Präsentation ist für 9:15 bis 10:00 PT geplant.
- None.
- None.
- Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company’s investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
The ASPEN-06 data will be featured in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier the same day.
2025 ASCO GI Presentation Details
Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).
Abstract Number: 332
Presenter: Kohei Shitara, M.D., Director of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan
Presentation Date and Time: Thursday, January 23, 9:15 a.m. – 10:00 a.m. PT
Session Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
Location: Level 2 Ballroom
Company Conference Call and Webcast Information
During the virtual company conference call and webcast event for investors, ALX company leadership will review the updated ASPEN-06 data. The event will be webcast live and a replay will be available after the call by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.”
Date & Time: Thursday, January 23, 1:00 p.m. PT/4:00 p.m. ET
Webcast Access: https://edge.media-server.com/mmc/p/ipy66o44
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
What is the ASPEN-06 Phase 2 trial investigating for ALXO's evorpacept?
When will ALX Oncology present the ASPEN-06 trial data at ASCO GI 2025?
Who will present ALXO's ASPEN-06 trial results at ASCO GI 2025?
When is ALX Oncology's virtual investor event to discuss ASPEN-06 data?
